Bionomics (ASX:BNO) announced that preclinical data from ongoing studies of BNC105, its vascular disrupting agent, will be presented during a poster session at the upcoming AACR-NCIEORTC International Conference on Molecular Targets and Cancer Therapeutics being held 5-9 November 2015 in Boston.
Preclinical results from a study of BNC105 in combination with the hypoxia-activated prodrug evofosfamide (previously known as TH-302) demonstrated encouraging synergistic activity in renal and breast cancer models, as indicated by enhanced tumour growth inhibition over monotherapy.
According to the company, in work completed after abstract submission but included in the poster, the combination of BNC105 and evofosfamide also demonstrated additive activity in a model of soft tissue sarcoma.
Evofosfamide is currently being evaluated in two fully recruited Phase 3 trials for the treatment of locally advanced unresectable or metastatic soft tissue sarcoma and locally advanced unresectable or metastatic pancreatic cancer by Threshold Pharmaceuticals and Merck KGaA.
Bionomics, Threshold Pharmaceuticals and Merck KGaA, collaborated on the preclinical evaluations of BNC105 and evofosfamide.
BNC105 was also studied in vivo in combination with antibodies that target PD-1 or CTLA4 in colorectal cancer xenograft models and data showed a synergistic relationship for the combination therapy when looking at inhibition of tumour growth.